The U.S Food & Drug Administration has granted approval for a targeted therapy called CABOMETYX ® to treat pancreatic ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma.

Common adverse reactions included fatigue, diarrhea, and pain, with similar profiles across treatment arms ... colorectal cancer. The FDA has approved nivolumab (Opdivo; Bristol Myers Squibb ...